Cyclopamine

For research use only. Not for use in humans.

目录号：S1146 别名： 11-deoxojervine 中文名称：环巴胺

CAS No. 4449-51-8

Cyclopamine (11-deoxojervine)是一种特异性Hedgehog (Hh)信号通路拮抗剂，作用于Smoothened (Smo)，在TM3Hh12细胞中IC50为46 nM。

规格

价格

库存

购买数量

5mg	RMB 1227.56	现货
25mg	RMB 3037.37	现货
50mg	RMB 3833.48	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Cyclopamine发表文献102篇：

Nature, 2021, 10.1038/s41586-021-03703-z

PubMed: 34234347 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14325

PubMed: 25938716 ( click the link to review the publication )

Neuron, 2021, S0896-6273(21)00506-7

PubMed: 34407390 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(29)e2101783118

PubMed: 34230098 ( click the link to review the publication )

Cancer Res, 2021, canres.0198.2021

PubMed: 34167949 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)418

PubMed: 33499351 ( click the link to review the publication )

Cell Death Dis, 2021, 12(5):459

PubMed: 33966040 ( click the link to review the publication )

Cell Death Dis, 2021, 12(5):495

PubMed: 33993198 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:675486

PubMed: 34164397 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16313

PubMed: 33507617 ( click the link to review the publication )

Sci Rep, 2021, 11(1):16243

PubMed: 34376787 ( click the link to review the publication )

Cancer Med, 2021, 10.1002/cam4.4018

PubMed: 34076346 ( click the link to review the publication )

Molecules, 2021, 26(9)2607

PubMed: 33946996 ( click the link to review the publication )

Oncol Lett, 2021, 21(4):295

PubMed: 33732371 ( click the link to review the publication )

Biology (Basel), 2021, 10(8)767

PubMed: 34439999 ( click the link to review the publication )

Can J Physiol Pharmacol, 2021, 10.1139/cjpp-2020-0588

PubMed: 33617370 ( click the link to review the publication )

J Orthop Surg Res, 2021, 16(1):160

PubMed: 33637095 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2021, 62(2):33

PubMed: 33616621 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16313

PubMed: 33507617 ( click the link to review the publication )

Nat Commun, 2020, 11(1):44

PubMed: 31896750 ( click the link to review the publication )

Cell Rep, 2020, 21;31(3):107521

PubMed: 32320667 ( click the link to review the publication )

Int J Cancer, 2020, 7

PubMed: 32383186 ( click the link to review the publication )

Stem Cell Reports, 2020, S2213-6711(20)30192-2

PubMed: 32589876 ( click the link to review the publication )

J Clin Endocrinol Metab, 2020, dgaa656

PubMed: 32936899 ( click the link to review the publication )
Stem Cell Res Ther, 2020, 11(1):488

PubMed: 33198821 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 20;2020:1868764

PubMed: 32377291 ( click the link to review the publication )

Proc Biol Sci, 2020, 287(1935):20192939

PubMed: 32933441 ( click the link to review the publication )

Chemosphere, 2020, 6;254:126709

PubMed: 32348926 ( click the link to review the publication )

Front Cell Neurosci, 2020, 14:575690

PubMed: 33343302 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(17)E6410

PubMed: 32899202 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Dev Biol, 2020, 457(1):128-139

PubMed: 31550483 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.2873

PubMed: 32030915 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2610-2620

PubMed: 33125122 ( click the link to review the publication )

Neural Plast, 2020, 2020:8815195

PubMed: 32802036 ( click the link to review the publication )

Front Pharmacol, 2020, 11:204

PubMed: 32194421 ( click the link to review the publication )

Dev Cell, 2019, 51(6):665-674.e6

PubMed: 31813796 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):3134-3152

PubMed: 31371388 ( click the link to review the publication )

Elife, 2019, 8e50208

PubMed: 31482846 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31658643 ( click the link to review the publication )

Hum Mol Genet, 2019, 28(6):896-911

PubMed: 30445456 ( click the link to review the publication )

J Cell Physiol, 2019, 234(3):2058-2066

PubMed: 30317648 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(8)E1991

PubMed: 31018557 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5386-5395

PubMed: 30367510 ( click the link to review the publication )

J Cell Biochem, 2019, 120(11):18979-18994

PubMed: 31245876 ( click the link to review the publication )

Exp Cell Res, 2019, 385(2):111671

PubMed: 31634481 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2019, 124(6):660-669

PubMed: 30548093 ( click the link to review the publication )

Hepatobiliary Pancreat Dis Int, 2019, 18(1):38-47

PubMed: 30243878 ( click the link to review the publication )
Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Neuron, 2018, 97(6):1235-1243

PubMed: 29526553 ( click the link to review the publication )

EMBO Rep, 2018, 19(2):269-289

PubMed: 29263200 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30014845 ( click the link to review the publication )

Lab Chip, 2018, 18(20):3184-3195

PubMed: 30204194 ( click the link to review the publication )

Exp Cell Res, 2018, 366(1):63-70

PubMed: 29548749 ( click the link to review the publication )

Mol Pain, 2018, 14:1744806918767560

PubMed: 29607715 ( click the link to review the publication )

Biol Reprod, 2018, 98(4):480-490

PubMed: 29329377 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):21-30

PubMed: 29115520 ( click the link to review the publication )

Cell Transplant, 2018, 27(3):393-406

PubMed: 29749250 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):995-1003

PubMed: 30106753 ( click the link to review the publication )

Int J Clin Exp Pathol, 2018, 11(5):2920-2930

PubMed: 31938417 ( click the link to review the publication )

Nat Commun, 2017, 8:14382

PubMed: 28176763 ( click the link to review the publication )

PLoS Genet, 2017, 13(8):e1006951

PubMed: 28797033 ( click the link to review the publication )

Cancer Discov, 2017,

PubMed: 28923910 ( click the link to review the publication )

Front Immunol, 2017, 9:2847

PubMed: 30568656 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 44(5):1856-1868

PubMed: 29237157 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):568-578

PubMed: 27709831 ( click the link to review the publication )

Exp Cell Res, 2017, 357(1):79-87

PubMed: 28461158 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 89:147-156

PubMed: 28624529 ( click the link to review the publication )

Mol Immunol, 2017, 92:68-75

PubMed: 29054053 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5605-5619

PubMed: 29200875 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42495-42509

PubMed: 28477008 ( click the link to review the publication )
Dev Cell, 2016, 39(2):239-253

PubMed: 27720610 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):682-94

PubMed: 27113760 ( click the link to review the publication )

J Med Chem, 2016, 59(24):11050-11068

PubMed: 27736063 ( click the link to review the publication )

Cell Biosci, 2016, 10.1186/s13578-016-0104-8

PubMed: 27313840 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:63

PubMed: 26048374 ( click the link to review the publication )

Development, 2015, 142(15):2610-22

PubMed: 26116667 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2569-89

PubMed: 26609469 ( click the link to review the publication )

Mol Carcinog, 2015, 10.1002/mc.22300

PubMed: 25728352 ( click the link to review the publication )

Int J Mol Med, 2015, 35(6):1641-50

PubMed: 25872645 ( click the link to review the publication )

Insect Sci, 2015, 22(5):587-96

PubMed: 25154865 ( click the link to review the publication )

Data Brief, 2015, 4:22-31

PubMed: 26217756 ( click the link to review the publication )

Stem Cell Reports, 2015, 5(5):816-828

PubMed: 26527387 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):544-59

PubMed: 24553082 ( click the link to review the publication )

Eur J Pharmacol, 2014, 10.1016/j.ejphar.2014.01.074

PubMed: 24534491 ( click the link to review the publication )

Mol Cell Biochem, 2014, 396(1-2):257-68

PubMed: 25064451 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbadis.2014.10.001

PubMed: 25305367 ( click the link to review the publication )

Insect Sci, 2014, 10.1111/1744-7917

PubMed: 25154865 ( click the link to review the publication )

Dev Biol, 2013, 381(2):312-23

PubMed: 23872235 ( click the link to review the publication )

Dev Cell, 2013, 25(2):169-81

PubMed: 23602386 ( click the link to review the publication )

Mol Cancer, 2013, 12:66

PubMed: 23786654 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 5;32(1):7

PubMed: 23379358 ( click the link to review the publication )

Toxicol Lett, 2013, 225(2):318-324

PubMed: 24388991 ( click the link to review the publication )

PLoS One, 2013, 8(3):e57346

PubMed: 23483902 ( click the link to review the publication )
Liver Int, 2013, 33(1):149-61

PubMed: 23121638 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Neuro Oncol, 2012, 14(12):1441-51

PubMed: 23104476 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2262-74

PubMed: 22396494 ( click the link to review the publication )

Cancer Lett, 2012, 322(2):169-76

PubMed: 22450749 ( click the link to review the publication )

Exp Hematol, 2012, 40(5):418-27

PubMed: 22240607 ( click the link to review the publication )

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述

Cyclopamine (11-deoxojervine)是一种特异性Hedgehog (Hh)信号通路拮抗剂，作用于Smoothened (Smo)，在TM3Hh12细胞中IC50为46 nM。

靶点

Smoothened ^[1]
(TM3Hh12 cells)

46 nM

体外研究

Cyclopamine 抑制Hedgehog信号通路， IC50 为46 nM, 且在[3H]Hh-Ag结合实验中，作用于CHO-K1细胞，抑制人类Smo受体活性，IC50为 280 nM。^[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞，显著抑制 Hedgehog通路活性，这种作用存在剂量依赖性，且浓度为3 μM时，抑制肿瘤细胞生长，抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果，说明Cyclopamine 特定作用于Hedgehog 通路，且没有毒性。^[2]通过与Smo直接作用而抑制Hedgehog信号，Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖，抑制达 75-80%,且使凋亡率提高2.5到 3.5倍，但是不影响BxPC3-SMOlow 细胞系。^[3] Cyclopamine 处理E3LZ10.7细胞系，显著降低Snail mRNA，且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞，显著抑制浸润型细胞, 使转移细胞降低500多倍，但是对Hedgehog非依赖性细胞系Panc-1没有影响。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
OS-RC-2	MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkHkTWM2OD13Lki2OlYh\|ryP	MljzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
DOHH-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV\iXZI1UUN3ME25MlM2Pjh7IN88US=>	MkDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
no-10	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX3JR\|UxRTlwOUCzPUDPxE1?	NVjSUIFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LS-513	NGn3O2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWDSbYRXUUN3ME2xNU4{PTR5IN88US=>	MknHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ALL-PO	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NELRXVlKSzVyPUGxMlc4OzRizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
8-MG-BA	NUPvcVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYrRc\|RPUUN3ME2xN{4yOTJ\|IN88US=>	M4jXTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
RPMI-8402	NHjZbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mk\sTWM2OD1zNT64OVM4KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
EoL-1-cell	NH;yVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4O2V2lEPTB;MUiuOVk1QCEQvF2=	NV7RW5YzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NALM-6	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUf5TmUzUUN3ME2xPU4xOTZ5IN88US=>	M2PYflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
DEL	NX[3N5dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1nQVWlEPTB;MkCuNVQ4OSEQvF2=	NEjCPJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
SR	M3jBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV;JR\|UxRTJ\|Lk[3NVUh\|ryP	MnPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
697	NVjwc2RCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEjKcIFKSzVyPUK2MlYyPTVizszN	NXntPXpNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
COLO-829	NVjRW5psT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYLFcJBXUUN3ME2yOk45PDh\|IN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
EVSA-T	MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYrNemw4UUN3ME2yO{42PTZzIN88US=>	NVHEW4JFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ATN-1	NYLSO2dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnjpTWM2OD1\|MT6yN\|I6KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
L-363	M3zt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3Pm[WlEPTB;M{GuO\|Q3OSEQvF2=	Mlm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LAMA-84	NV23VHpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXHJR\|UxRTN{LkWyNVEh\|ryP	NWj5clV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NOS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFi4bXBKSzVyPUO0MlI6PTZizszN	NFW1OGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
BB30-HNC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2nzW2lEPTB;M{SuN\|MxPiEQvF2=	M1O1[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
BC-1	MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYfjfVk5UUN3ME2zO{46PzR4IN88US=>	MkP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
IST-SL2	NEXnfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1HiNWlEPTB;M{iuNlI1KM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
D-392MG	NUXrOnNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX7JR\|UxRTRyLkKyNVUh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
no-11	Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVjJR\|UxRTRyLkW1NlEh\|ryP	MlXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LC4-1	M4PUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVrJR\|UxRTRyLki3NVYh\|ryP	NEjIPFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
A388	NHixcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXjJR\|UxRTR{LkW4OFgh\|ryP	MmnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWDJR\|UxRTR{LkewO\|Qh\|ryP	NG\tXJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
CESS	NYX4PItGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{H6emlEPTB;NESuNlI{OiEQvF2=	NFTCWHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
RS4-11	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWXJR\|UxRTR7LkC5N\|gh\|ryP	M1nufFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MS-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn\VTWM2OD13MD65N\|UyKM7:TR?=	NIPtfGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
CTV-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV;JR\|UxRTVzLkC3OEDPxE1?	NE\vU2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
D-502MG	NVu2OYwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkHZTWM2OD13MT62NlcyKM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ML-2	M33WdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUjJR\|UxRTV{LkmxPVUh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
SK-NEP-1	NYHz[3lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX3I[2doUUN3ME21N{4{QTJ\|IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LOXIMVI	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUXVdHZRUUN3ME21N{42QDh2IN88US=>	M1LQRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
DJM-1	NGi4VJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYTZSVU3UUN3ME21Ok4{OzlzIN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
GI-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUDJR\|UxRTV4Lk[xOFkh\|ryP	NHe3NZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
IST-MES1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2LVSmlEPTB;NkCuOVQ6OyEQvF2=	NV30NZVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MV-4-11	NVvjOJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NITpTWVKSzVyPU[wMlY2OzhizszN	Mo[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
OVCAR-4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4\jeWlEPTB;NkOuOVY2PyEQvF2=	M4O1O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KE-37	M2TVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2nVZmlEPTB;Nk[uNlY3QCEQvF2=	MljjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
D-542MG	MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEXod41KSzVyPU[4MlQyOzVizszN	NEXZbmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MHH-PREB-1	NXjTXm1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NULPZ3I6UUN3ME23Nk45PDRzIN88US=>	NXXib\|dORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MRK-nu-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYT3W\|B2UUN3ME23N{41PzB3IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
D-247MG	M{\NXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3q4emlEPTB;N{OuOVQ1OiEQvF2=	M1XySVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
OCI-AML2	M4fYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWfJR\|UxRTd4LkmzOlkh\|ryP	MmS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LP-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUnJR\|UxRTh{Lki3N\|Eh\|ryP	MoXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HCC1599	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3zYOmlEPTB;OESuNlg{PyEQvF2=	MmXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KARPAS-45	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{DVSWlEPTB;OESuOlk6OiEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
BE-13	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGTiV4RKSzVyPUm5MlA1PzdizszN	M1j6WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
GCIY	NWHoR3Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIXw[W9KSzVyPUm5MlA6PTRizszN	NWjlT5hmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
BV-173	NVO1T4VvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYmze5dIUUN3ME2xNFAvOzJ3IN88US=>	NUC3XoNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LB2518-MEL	NHi4[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUDwVpJ5UUN3ME2xNFAvPzh7IN88US=>	NUm0PVhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KS-1	NUTOSYkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2e0dGlEPTB;MUCxMlY{QSEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MOLT-16	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYTJR\|UxRTFyND65PFYh\|ryP	MkfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H1770	M3u0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mm[zTWM2OD1zMEiuO\|g1KM7:TR?=	NVfIU3RMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-H82	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYXHUGU5UUN3ME2xNVAvQTd4IN88US=>	M3X2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NCCIT	M1u4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX7ZRZFbUUN3ME2xNVIvPTJ7IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KALS-1	NFy4WWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUTJR\|UxRTFzNT65OFEh\|ryP	NGraZ4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
LB2241-RCC	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWDqPVNGUUN3ME2xNVYvPjd7IN88US=>	NIrHR\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HH	NHO3OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHvzR3lKSzVyPUGxO{4{QTVizszN	MmXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HD-MY-Z	MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH\J[W9KSzVyPUGxPE41QDhizszN	NFPae2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
EB-3	NXu4emlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVXJR\|UxRTF{Mz6wPVQh\|ryP	Mo\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BL-70	M4\uWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFmyU\|ZKSzVyPUGyN{4yOjdizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
K-562	M2njW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEnvb2pKSzVyPUGyOk4zPDVizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HT-144	M2XEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWnJR\|UxRTF\|Mz6xOlQh\|ryP	M1PzR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
PF-382	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mo[0TWM2OD1zM{SuN\|YyKM7:TR?=	M2\McVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
RPMI-8226	MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVHtOm5jUUN3ME2xN\|UvODR3IN88US=>	MkWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H1355	MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFLYSFdKSzVyPUGzOU42QDdizszN	Ml\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LXF-289	M4DpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGjVcnFKSzVyPUGzPU44QDFizszN	NF3iXJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H69	NF73UGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFHCZnJKSzVyPUG0Nk46OzJizszN	Mny5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	NWPUSnQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX7kXY1OUUN3ME2xOFcvOTNizszN	M17lNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KARPAS-299	M1LIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXWw[XZ2UUN3ME2xOFkvOTJizszN	NEjqNZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
GB-1	NIH4e3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1PFWmlEPTB;MUS5MlMzOiEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
CMK	M33HfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYnLdHJpUUN3ME2xOFkvPTF3IN88US=>	NWHLU\|BCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MPP-89	NFPjXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH7OVYNKSzVyPUG1Ok4xOzVizszN	Mlj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KU812	MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn3FTWM2OD1zNkGuPVAzKM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
REH	NGDwcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoLKTWM2OD1zNkKuNVI2KM7:TR?=	NEfXcpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NEC8	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkCyTWM2OD1zNkWuNFI3KM7:TR?=	NFnmOVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KP-N-YS	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFPPPYRKSzVyPUG2PE4{QTVizszN	M4HnR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	NGTQRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV\JR\|UxRTF4OT65NVUh\|ryP	M1zyelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
Becker	M1[xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF7ne5lKSzVyPUG3OE4yQCEQvF2=	NUXMc4FQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LB647-SCLC	M363bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1npU2lEPTB;MUe1Mlg1PSEQvF2=	M17nWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LU-139	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVfJR\|UxRTF5OD6wNVkh\|ryP	M4rJXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
QIMR-WIL	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVz5UI9ZUUN3ME2xO\|kvPjR4IN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-H1395	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYfJR\|UxRTF5OT65PVYh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NOMO-1	NULGdG5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYmwW2U{UUN3ME2xPFIvQDVizszN	M{\qW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
GI-ME-N	NETCeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGnOdIVKSzVyPUG4O{46PjlizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KMS-12-PE	NUjrdGpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXjJR\|UxRTF6OT6yO\|Mh\|ryP	NEX6N4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
Daudi	NFrEVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVjTPHVHUUN3ME2xPVEvOTJ6IN88US=>	NHjqR3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
LB996-RCC	MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFPodIdKSzVyPUG5NU43QTlizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-H2107	NWHXWZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX\JR\|UxRTF7Mz63N\|kh\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
SK-PN-DW	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGPOemdKSzVyPUG5OE44OTlizszN	MmLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
MC-CAR	NX3oSGE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVL5fGxZUUN3ME2yNFIvOjV\|IN88US=>	NYr1ZVBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
SNB75	NWjXTHJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NE\BOHJKSzVyPUKyNU46PCEQvF2=	M2TyfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
ES4	NYfiUnpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUHJR\|UxRTJ{Mz63PFMh\|ryP	M4PndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KARPAS-422	NGjjN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEXEXG1KSzVyPUKyPE4{PTJizszN	NVviU2NuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-H1648	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4i3WGlEPTB;MkK5MlQ5QSEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ES6	MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVHJR\|UxRTJ\|OT60N{DPxE1?	NIHndWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KNS-81-FD	M2DURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkXITWM2OD1{NEGuNVk4KM7:TR?=	MlHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
JAR	NVzmcGpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFuwWJZKSzVyPUK1Ok4zOjVizszN	M{e0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NB1	NYDPeHN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MojyTWM2OD1{NkCuOVE3KM7:TR?=	NH60PWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
D-336MG	NXXVOlVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEXNVXdKSzVyPUK2NE43QThizszN	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
BC-3	NVzLRZZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYDa[5V1UUN3ME2yOlUvOTd6IN88US=>	MmD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HCC2218	M3r3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYPiZ402UUN3ME2yOlYvPDF3IN88US=>	NFTwUHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
TE-9	NGXjVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnPtTWM2OD1{Nk[uOlI4KM7:TR?=	MkfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3PIe2lEPTB;Mk[2Mlc2OyEQvF2=	M3zhOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
CTB-1	M1nZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXK0eJNiUUN3ME2yOlkvQTd\|IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NB7	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVXJR\|UxRTJ5MTFOwG0>	NIrLTXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ST486	NITkNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIPCTnVKSzVyPUK3O{41OTJizszN	NEK3O3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HCC1187	NGPl[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVrJR\|UxRTJ6Mj64NVEh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-SNU-16	NWjjPFc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXrJR\|UxRTJ6ND6yOFgh\|ryP	NHXvTWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
COR-L279	NUnNXIttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWjJR\|UxRTJ7MT61PFQh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ES8	M{jRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4jyfWlEPTB;Mkm0MlE5OiEQvF2=	NV30eoJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
U-698-M	NWK4fWc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVnJR\|UxRTJ7OD6yOFMh\|ryP	Mk\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HEL	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn3HTWM2OD1\|MEmuNVQ6KM7:TR?=	NGPjbG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KINGS-1	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2PlXGlEPTB;M{GwMlY4PCEQvF2=	NXTOR5o{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KY821	M17vWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWXUTnhkUUN3ME2zN\|YvPTl3IN88US=>	NUHxNVZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MZ1-PC	M1i2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVXrXIppUUN3ME2zOFUvPjF6IN88US=>	NIX2WJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
LS-411N	MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUTBSG9TUUN3ME2zOVQvPjZizszN	MnzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SIG-M5	M4DSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX61WHJUUUN3ME2zOVkvPzh{IN88US=>	M{W0N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HT	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NILZfnZKSzVyPUO2O{44OTFizszN	NFLDUW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HC-1	NYLHPXhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEH5fHRKSzVyPUO2O{44QDdizszN	MofvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H1694	M4\Gcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mlq0TWM2OD1\|N{KuPVM1KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
BB65-RCC	MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHS4bINKSzVyPUO3Ok4zPDVizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HAL-01	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3m0c2lEPTB;M{e5Mlg{QCEQvF2=	NVPuSFRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ARH-77	NYfVfndwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1rx[2lEPTB;M{m0MlAxQCEQvF2=	Mk[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
MZ7-mel	NUDKSGpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NY\oSpQ6UUN3ME2zPVcvOjN\|IN88US=>	M4fRSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SIMA	Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MljyTWM2OD12MEOuPVM{KM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
DG-75	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWHIe5lGUUN3ME20NVUvPjl6IN88US=>	NXL1fFVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
HUTU-80	NVvBW296T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX\QNlhNUUN3ME20NVkvOTh3IN88US=>	Ml3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KNS-42	NXXQbZFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH63UVVKSzVyPUSyOU45OTVizszN	M{HRdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SH-4	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXjGeJZLUUN3ME20NlcvPTZ3IN88US=>	Mnz3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
L-540	NXPkSW9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV\NcmJ7UUN3ME20N\|EvODNzIN88US=>	NHzQbXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NB10	MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoLVTWM2OD12NEGuNlM1KM7:TR?=	M{jUXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
ES1	M2rKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWPJR\|UxRTR3Mj63OVMh\|ryP	NULpdHg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KMOE-2	NHS5SHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{XqfWlEPTB;NEW2MlcyOSEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MC116	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2n5TmlEPTB;NEW4MlEyPiEQvF2=	NH7VO2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
RCC10RGB	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NITJN4tKSzVyPUS2NE4xODVizszN	M{\sTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
RL95-2	NYW1XmplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIPlUm9KSzVyPUS2NE4zOzdizszN	NUe3T5dWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
Raji	M3[3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIjkTnlKSzVyPUS2PE4yPDNizszN	NHu1R3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
CAS-1	NInZbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGDuNVVKSzVyPUS3Nk4xPzNizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
Calu-6	NVThOmV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUDJR\|UxRTR5NT6yOlUh\|ryP	MlzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KG-1	NGX2epVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXfJR\|UxRTR5OD60OEDPxE1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LB771-HNC	M3;TVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{nTVGlEPTB;NEiyMlI{OiEQvF2=	MkT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ACN	NFL1UVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnP3TWM2OD12OUOuOVk6KM7:TR?=	M1rkOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KM12	M3vwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXLJR\|UxRTR7Nj61PFkh\|ryP	MnzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
U2OS	MX3GeY5kfGmxbjDhd5NigQ>?			MkD2Rolv\GmwZzDh[oZqdmm2eTD0c{B4cWymIIT5dIUhW22xIHX4dJJme3OnZDDpckBWOk:VIHPlcIx{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEumIE2gNE4xOTJ2IN88UU4>	NWTjVFl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
U2OS	M4W1SWZ2dmO2aX;uJIF{e2G7		MYOyJIhzew>?	NIfhdGpFcXOybHHj[Y1mdnRib3[gX\|NJZWO7Y3zvdIFucW6nIH\yc40hf2muZDD0fZBmKFOvbzDlfJBz\XO\|ZXSgbY4hXTKRUzDj[YxteyCjZoTldkAzKGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDLbUA:KDBwMEGyO{DPxE1w	M{D4[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[zOVIzLz5{M{C2N\|UzOjxxYU6=
TM3	MlL5SpVv[3Srb36gZZN{[Xl?		MUG0PEBpenN?	NIjZd3RKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIGTNN{Bk\WyuczDi[YFzcW6pIIDURU05gEeuaT3MeYMhemWyb4L0[ZIh[2:wc4TyeYN1KGG\|c3Xzd4VlKGG\|IITyZY5{[3KrcITpc45idCCvb3T1cIF1cW:wIH;mJGdtcSCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SCjc4PhfUwhUUN3MDC9JFAvODR4IN88UU4>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB7MUW1PUc,OTlyOUG1OVk9N2F-
HCC827	NHfSUW9HfW6ldHnvckBie3OjeR?=			M2DkOmRqe3CuYXPlcYVvfCCxZjDbN2heNWO7Y3zvdIFucW6nIH\yc40hW02RIG[0NFROKG23dHHueEBqdiCpZX\peIlvcWJicnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\WyuczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDLbUA:KDBwMEWxJO69VS5?	M2DLVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{i3NVU3Lz5{OEe4O\|E2PjxxYU6=
HEK293	MXnGeY5kfGmxbjDhd5NigQ>?		M2D2[lIhcHK\|	NVO1e25LTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3sZYJmdGynZDDjfYNtd3CjbXnu[UBnem:vIHj1cYFvKFOvbzDy[YNmeHSxcjDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHmeIVzKDJiaILzJIJ6KG[udX;y[ZNk\W6lZTDtbYNzd3Olb4D5MEBKSzVyIE2gNE4xPjRizszNMi=>	NUH5UI1JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2PTFpPkKyNlY5PTVzPD;hQi=>
Shh Light2	MoDWSpVv[3Srb36gZZN{[Xl?		NVvZXI94OzBiaILz	NUi4WHNqUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDTbIghVGmpaISyJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2Zic3;ubYMhcGWmZ3Xoc4cucW6mdXPl[EBIVElzLX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCvZXHzeZJm\CCjZoTldkA{OCCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjB5NEGg{txONg>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV4N{O3NUc,Ojd3NkezO\|E9N2F-
U2OS	MXLGeY5kfGmxbjDhd5NigQ>?			MUTCbY5lcW6pIHHm[olvcXS7IITvJHNudyCGNEezTEBufXSjboSg[ZhxemW\|c3XkJIlvKFV{T2OgZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3SgQUAxNjFzNjFOwG0v	NXfyUodTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
DaOY	MnvkSpVv[3Srb36gZZN{[Xl?		MoiwOFghcHK\|	M17wTGlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJIh2dWGwIFThU3kh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhT2yrMTDtVm5CKGW6cILld5Nqd25iYX\0[ZIhPDhiaILzJIJ6KFKWLWDDVkBidmGueYPpd{whUUN3MDC9JFAvOTZizszNMi=>	NF72SW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
U2OS	NWnmRVk{TnWwY4Tpc44h[XO\|YYm=		M3rHV\|IhcHK\|	NIPxfGdFcXOybHHj[Y1mdnRib3[gX\|NJZWO7Y3zvdIFucW6nIH\yc40hW22xIFS0O\|NJKG23dHHueEBmgHC{ZYPz[YQhcW5iVULPV{Bk\WyuczDh[pRmeiB{IHjyd{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBMcSB;IECuNlMzKM7:TT6=	NVHKW41QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
CHO	NFf6bVRHfW6ldHnvckBie3OjeR?=			NWK3V4RSSW62YXfvcol{fCCjY4Tpeol1gSCjdDDoeY1idiCVbX:gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKEOKTzDj[YxteyCkeTDbN2heUGhvQXegZolv\GmwZzDhd5NigSxiSVO1NEA:KDBwMkig{txONg>?	M1iwV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEmxOVU6Lz5zOUC5NVU2QTxxYU6=
Shh Light2	NET0TWFHfW6ldHnvckBie3OjeR?=		NIDLWWQ1OCCqcoO=	MVLJcohq[mm2aX;uJI9nKFOKSDDwZZRpf2G7IHnuJI1wfXOnIGPobEBNcWeqdEKgZ4VtdHNiYX\0[ZIhPDBiaILzJIJ6KEeuaT3k[ZBmdmSnboSgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5\|IN88UU4>	NHLZ[pY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW5Nlc5QCd-MkG1PVI4QDh:L3G+
Shh-light2	MmPxSpVv[3Srb36gZZN{[Xl?			NGLEbIdKdmirYnn0bY9vKG:oIGPtc{1u\WSrYYTl[EBJcCC\|aXfuZYxqdmdiaX6gbJVu[W5iU3joMYxq\2i2MjDj[YxteyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjNizszNMi=>	M1fuWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
M210B4	NX36Nm9mTnWwY4Tpc44h[XO\|YYm=		NHP0e5IzPCCqcoO=	NFLQ[IFKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBud3W\|ZTDNNlExSjRiY3XscJMh[XO\|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiUITjbEBuWk6DIHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyxiSVO1NEA:KDBwNEOg{txONg>?	M3Oz[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|E3Lz5{NEmwNFcyPjxxYU6=
Shh-Light 2	MkTqSpVv[3Srb36gZZN{[Xl?		M33uUlIh\GG7cx?=	MVPBcpRi\2:waYP0JIFkfGm4aYT5JIF1KFOvbzDpckBud3W\|ZTDTbIguVGmpaISgNkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPobE1qdmS3Y3XkJGdtcTFvcnXwc5J1\XJiYXP0bZZqfHliYX\0[ZIhOiCmYYnzJIJ6KGS3YXytcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIH3leIhw\CxiSVO1NEA:KDBwNEi0JO69VS5?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4M{WyNkc,OjNyNkO1NlI9N2F-
Shh Light2	NI\IZ2hHfW6ldHnvckBie3OjeR?=			MXXJcohq[mm2aX;uJI9nKFOKSDDpckBud3W\|ZTDTbIghVGmpaISyJINmdGy\|IHL5JGdNUS2{ZYPwc45{cX[nIH\pdoVndHlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzVyIE2gNE42KM7:TT6=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTNyOUC4NEc,OTl\|MEmwPFA9N2F-
C3H10T1/2	MlHoSpVv[3Srb36gZZN{[Xl?			NH;KcWhKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygV2hJKGGldHn2ZZRm\CCyYYToe4F6KGmwIH3veZNmKEN\|SEGwWFEwOiClZXzsd{Bie3Onc4Pl[EBieyCVQVetbY5lfWOnZDDj[YxtKGSrZn\ldoVvfGmjdHnvckBjgSCjbHvhcIlv\SCyaH;zdIhifGG\|ZTDhd5NigSxiSVO1NEA:KDBwNjFOwG0v	NXy0WVJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1PVI4QDhpPkKxOVkzPzh6PD;hQi=>
C3H10T1/2	NIL4VXlHfW6ldHnvckBie3OjeR?=		M1\xZVYhcHK\|	MXjJcohq[mm2aX;uJI9nKFODRz3pcoR2[2WmIHTp[oZmemWwdHnheIlwdiCxZjDtc5V{\SCvZYPlcoNpgW2jbDDwcJVzcXCxdHXueEBEO0hzMGSxM\|Ih[2WubIOgeI8h[WytYXzpcoUheGixc4DoZZRie2VicH;zbZRqfmVib3Xz[Y9jdGG\|dIOgZYZ1\XJiNjDodpMtKEmFNUCgQUAxNjZ{IN88UU4>	M4m3dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
ASZ001	NYLKTFRZTnWwY4Tpc44h[XO\|YYm=		NH3ZZZI1QCCqcoO=	NEPlOJJKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBud3W\|ZTDBV3oxODFiY3XscJMh[XO\|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiR3zpNUBuWk6DIHX4dJJme3Orb36gZYZ1\XJiNEigbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyxiSVO1NEA:KDBwNk[g{txONg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEexOkc,OjR7MEC3NVY9N2F-
M210B4	M3voTWZ2dmO2aX;uJIF{e2G7		M2K0VFI1KGi{cx?=	M2flZ2lvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIF2yNVBDPCClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC56IN88UU4>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEexOkc,OjR7MEC3NVY9N2F-
medulloblastoma cells	NWHwNpo3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NF;3N2RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIH3l[JVtdG:kbHHzeI9u[SClZXzsd{Bp[XKkb4LpcochcGW2ZYLvfplod3W\|IID0Z4gyKGenbnWgZpkhVVSWIHHzd4F6NCCHQ{WwJF0hOSEQvF2u	M2fNS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEG3OlMyLz5zN{SxO\|Y{OTxxYU6=
CHO	MYXGeY5kfGmxbjDhd5NigQ>?			NFLmdWxCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IH3veZNmKFOvbzDy[YNmeHSxcjDlfJBz\XO\|ZXSgbY4hS0iRIHPlcIx{KGK7IGuzTH1JcC2DZzDibY5lcW6pIHHzd4F6NCCLQ{WwJF0hOS5{IN88UU4>	NFvLfGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC5NVU2QSd-MUmwPVE2PTl:L3G+
Shh-Light2	M37tRWZ2dmO2aX;uJIF{e2G7		NVnWeFY4PDhiaILz	MYrJcohq[mm2aX;uJI9nKFOKSDDpckBud3W\|ZTDTbIguVGmpaISyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCJbHmxJJJmeG:{dHXyJIdmdmViYYPzZZkhcW5icILld4Vv[2Vib3[gV2FINCCLQ{WwJF0hOS5\|MUKg{txONg>?	NIrQR2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUW0NVQ6OCd-MUm1OFE1QTB:L3G+
MEF	NULvW5pJTnWwY4Tpc44h[XO\|YYm=			MWfJcohq[mm2aX;uJI9nKFOvbzDpckBud3W\|ZTDQeINpNWSnZnnjbYVvfCCPRV[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVaHitbY5lfWOnZDDHcIkyKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUwhUUN3MDC9JFEvPSEQvF2u	NGfSdIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C3OFU1OSd-MkOwO\|Q2PDF:L3G+
MEF	NGH3fFZHfW6ldHnvckBie3OjeR?=		M{TmXFMxKGi{cx?=	M3uxRmlvcGmkaYTpc44hd2ZiU33vJIlvKG2xdYPlJHB1[2hvZHXmbYNq\W62IF3FSkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPobE1qdmS3Y3XkJGdtcS2{ZYPwc45{cX[nIHLleIFo[WyjY4Tvd4ll[XOnIHHjeIl3cXS7IHHmeIVzKDNyIHjyd{BjgSCEZYThS2xwKGG\|c3H5MEBKSzVyIE2gNU46KM7:TT6=	MmS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyN{S1OFEoRjJ\|MEe0OVQyRC:jPh?=
neural precursor cells	M1m0PWFvfGmycn;sbYZmemG2aY\lJIF{e2G7			M1nPeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2VibnX1doFtKHC{ZXP1dpNweiClZXzsd{BjgSClb3zvcpkh\m:{bXH0bY9vKGG\|c3H5MEBGSzVyIE2gNVMvPDRizszNMi=>	NUXhSolRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NVc3OzFpPkG3OFE4PjNzPD;hQi=>
U87	NEX6PYZEgXSxdH;4bYNqfHliYYPzZZk>			MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVPFch[2WubIOgZZN{\XO\|ZXSgZZMhfmmjYnnsbZR6KGmwIIDy[ZNmdmOnIH;mJIJmfGFiZ3z1Z5Vzd26rZHHz[UwhUUN3MDC9JFE2NjVizszNMi=>	MoSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMU[5NFQoRjJyMUG2PVA1RC:jPh?=
U87MG	M2C1e2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NUTVOlVwPzJiaILz	NYT3PFhlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNlIvPSEQvF2u	M3qxVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkK2OlU4Lz5{MkKyOlY2PzxxYU6=
A549	NWXISWFoSW62aXPhcoNmeiCjc4PhfS=>			NEHqdlNCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BjgSCPVGOgZZN{[XluIFnDOVAhRSB2OTFOwG0v	NYj3UpBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyNlE5PzJpPkG4NlIyQDd{PD;hQi=>
DU145	M3Wz[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NIXF[FQ2KHWP	M1Hkdlk3KGi{cx?=	MmK2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[XRiNTD1UUBi\nSncjC5OkBpenN?	M4XmflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkS5NVI2Lz5zOEK0PVEzPTxxYU6=
DU145	M4PXbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFL4VYIyOCC3TR?=	NWG3UpM4QTZiaILz	MnGwS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[XRiMUCgeW0h[W[2ZYKgPVYhcHK\|	NXzFelU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFkyOjVpPkG4NlQ6OTJ3PD;hQi=>
HEK293	NFTlbZpHfW6ldHnvckBie3OjeR?=			MUHJcohq[mm2aX;uJI9nKGKndHGg[4Ft[WO2b4Pp[IF{\SCrbjDISWszQTNiY3XscJM>	NELRb\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
22Rv	MU\GeY5kfGmxbjDhd5NigQ>?			Mmi2VoVlfWO2aX;uJI9nKGW6cILld5Nqd25ib3[gVHREUCCvUl7BJIlvKGi3bXHuJFIzWnZiY3XscJM>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR7NEe2Okc,OTd2OUS3OlY9N2F-
PANC1	NXzxOoJjTnWwY4Tpc44h[XO\|YYm=	NIG3UogxNjJidV2=	M363SVI1KGi{cx?=	NGLjNXJKdmirYnn0bY9vKG:oIFjoM2dNUTFvbXXkbYF1\WRiUGTDTEBuWk6DIHX4dJJme3Orb36gbY4hcHWvYX6gVGFPSzFiY3XscJMh[XRiMD6yJJVOKGGodHXyJFI1KGi{czDifUBTXC2SQ2K=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR3MEG3NEc,OjB2NUCxO\|A9N2F-
PANC1	NFnZV5NHfW6ldHnvckBie3OjeR?=	NXnkOWJCOC52IIXN	NWfuU2J7OjRiaILz	NUPNSJNCUW6qaXLpeIlwdiCxZjDIbE9IVElzLX3l[IlifGWmIGDUR2ghdVKQQTDlfJBz\XO\|aX;uJIlvKGi3bXHuJHBCVkNzIHPlcIx{KGG2IECuOEB2VSCjZoTldkAzPCCqcoOgZpkhWlRvUFPS	M2X4TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEWwNVcxLz5{MES1NFE4ODxxYU6=
Shh Light2	NX\W[ZozTnWwY4Tpc44h[XO\|YYm=	MoHXOk4zPSC3TR?=	MVqzNEBpenN?	M4X5U2lvcGmkaYTpc44hd2ZiTj3wZYxucXSxeXzheIVlKFOqaDDpckBud3W\|ZTDTbIghVGmpaISyJINmdGy\|IHH0JFYvOjVidV2gZYZ1\XJiM{CgbJJ{KGK7IH\pdoVndHlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5	MlvmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzNUG3N\|EoRjF7MUWxO\|MyRC:jPh?=
U87MG	MVnGeY5kfGmxbjDhd5NigQ>?	MWOxNEB2VQ>?	MoT0OEBpenN?	NVfYSIhkUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCmb4fuJJJm\3WuYYTpc44hd2ZiR3zpNUBifCBzMDD1UUBi\nSncjC0JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ{Nk[1O{c,OjJ{Mk[2OVc9N2F-
HEK293	NIHYfllHfW6ldHnvckBie3OjeR?=	NYnqVYFOPSC3TR?=	MYWxNEBpenN?	NHKxR\|ZFcXOybHHj[Y1mdnRib3[gRm9FUVC\LXP5Z4xweGGvaX7lJIZzd21iaIXtZY4hW22xIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYSgOUB2VSCvZXHzeZJm\CCjZoTldkAyOCCqcoOgZpkhTEGSSTDzeIFqdmmwZzDiZZNm\CCobIXvdoV{[2WwY3WgcYlkem:\|Y3;wbYMh[XO\|YYm=	NXy5bIN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3N\|YxPjNpPkK3O\|M3ODZ\|PD;hQi=>
HEK293	NF;SWmtHfW6ldHnvckBie3OjeR?=	NVTZdnZDPSC3TR?=	MmG0NVAhcHK\|	Mnj6SIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2leXPsc5BidWmwZTDmdo9uKGi3bXHuJHNudyCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGG2IEWgeW0hdWWjc4Xy[YQh[W[2ZYKgNVAhcHK\|IHL5JGZCS1NiYX7hcJl{cXN?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd\|NkC2N{c,Ojd5M{[wOlM9N2F-
C3H10T1/2	M4DFN2Z2dmO2aX;uJIF{e2G7	NY\lVG4zPTVwNTD0c{A1PTByIH7N		M2fqNmNwdXCndHn0bZZmKGmwaHnibZRqd25ib3[gV41wKGmwIH3veZNmKEN\|SEGwWFEwOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNCTy2rbnT1Z4VlKEeuaUGgeJJidnOlcnnweIlwdmGuIHHjeIl3cXS7IHH0JFU2NjVidH:gOFUxOCCwTTDifUByWEOUIHHuZYx6e2m\|	MmTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyN{S1OFEoRjJ\|MEe0OVQyRC:jPh?=
U2OS	NVWzXVQ3TnWwY4Tpc44h[XO\|YYm=	NX3IeZFXPSC3TR?=	NFvUflE3KGi{cx?=	MljERY51[WexbnnzeEBi[3Srdnn0fUBifCClaHnt[ZJq[yCVbX:gOlM{KG23dHHueEBmgHC{ZYPz[YQhcW5iVULPV{Bk\WyuczDjc4V5eHKnc4Ppcoch[mW2YTDhdpJme3SrbkKtS2ZRKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhcW62cnHj[YxtfWyjcjDi[ZRiKGG{cnXzeIlvOi2JRmCgZYdoemWpYYTlJIZwem2jdHnvckBifCB3IIXNJIFnfGW{IE[gbJJ{KGK7IHPvcoZw[2GuIH3pZ5Jwe2OxcIm=	MojJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ\|ME[zOVIzRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Snail / E-cadherin / Slug / Vimentin ; PubMed: 26859575 Oncotarget SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT. Gli1 / TGF-β1 / CXCR4; PubMed: 26137001 Oncol Lett Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h. NF-κB / Cyclin D1 / MMP2 / MMP9; PubMed: 23599805 Oncol Lett Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9.	26859575 26137001 23599805
Immunofluorescence	PCNA / β-catenin; PubMed: 28747625 Sci Rep Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times. Vimentin; PubMed: 24553082 Cancer Biol Ther Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry.	28747625 24553082

体内研究

Cyclopamine 每天按50 mg/kg剂量处理小鼠，持续22天，消除HUCCT1移植瘤，且没有明显副作用。^[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天，前者诱导明显的肿瘤细胞凋亡，后者降低肿瘤质量，降低达50-60%，但是作用于BxPC3-SMOlow肿瘤没有效果。^[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤，显著抑制肿瘤转移，且和 Gemcitabine联用处理，完全废除转移。^[4]

激酶实验：^[1]	- 合并激酶实验: Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数，测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验，然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上，与Cyclopamine在37^oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上，然后在37^oC下温育。48小时后，在实验板中加入Bright-Glo或MTS，然后在492 nm处测定发光度或吸光度。通过分析反应曲线，使用R统计软件包测定IC50值。
细胞实验：^[2]	- 合并 Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116 Concentrations: 溶于DMSO, 终浓度为3 μM Incubation Time: 4天 Method: 在96孔板上，用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定，进行2和4天，然后在490 nm处通过测定光密度而测定存活细胞。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠 Dosages: 50 mg/kg/day Administration: 皮下注射处理 (Only for Reference)

参考文献

[4] Feldmann G, et al. Cancer Res, 2007, 67(5), 2187-2196.

- 合并

溶解度 (25°C)

体外	DMF	10 mg/mL warmed (24.29 mM)
	Ethanol	2 mg/mL warmed (4.85 mM)
	DMSO	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Cyclopamine SDF

分子量	411.62
化学式	C₂₇H₄₁NO₂
CAS号	4449-51-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	11-deoxojervine

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound for in vivo use in mice?
回答：
One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

用于临床的Smoothened抑制剂

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
最新的Smoothened抑制剂

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened激活剂

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

研究领域

产品类型

定制您的化合物库

Cyclopamine

客户使用Selleck生产的Cyclopamine发表文献102篇：

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Cyclopamine SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品